1. Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymphnode resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8:881–888
2. Latosinsky S, Dabbs K, Moffat F (2008) Evidence-based reviews in surgery group. Canadian Association of General Surgeons and American College of Surgeons Evidence-Based Reviews in Surgery. 27. Quality-of-life outcomes with sentinel node biopsy versus standard axillary treatment in patients with operable breast cancer. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Can J Surg 51(6):483–485
3. Chung MH, Ye W, Giuliano AE (2001) Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol 8:688–692
4. Wong SL, Chao C, Edwards MJ et al. (2002) Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg. 2001 Jun;67(6):522–6; discussion 527–8. Erratum in: Am Surg 68(5):503
5. Beumer JD, Gill G, Campbell I et al (2014) Sentinel node biopsy and large (≥3 cm) breast cancer. ANZ J Surg. 84(3):117–120